Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03665441
Title Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)
Acronym Trybeca-1
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors ERYtech Pharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA

Facility Status City State Zip Country Details
Arizona Cancer Center Scottsdale Arizona 85258 United States Details
St. Joseph Heritage Healthcare Fullerton California 92835 United States Details
University of California Davis Medical Center Sacramento California 95817 United States Details
Georgetown University Hospital Washington District of Columbia 20057 United States Details
Boca Raton Regional Hospital Boca Raton Florida 33486 United States Details
Ochsner Clinic Foundation New Orleans Louisiana 70121 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
University of Minnesota Health Clinics and Surgery Center Minneapolis Minnesota 55455 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Weill Cornell Medicine New York New York 10021 United States Details
University of Rochester Medical Center Rochester New York 14642 United States Details
Stony Brook University Stony Brook New York 10021 United States Details
Duke University Durham North Carolina 27705 United States Details
Medical Oncology Associates Spokane Washington 99208 United States Details
Institut de Cancerologie Brest 29609 France Details
Hammersmith Hospital London W12 0HS United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field